VENLO, Netherlands, July 13, 2017 /PRNewswire/ -- QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on resultsfor the second quarter and first half of 2017 on Thursday, July 27, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (EDT). A conference call is planned for Friday,
Conference Call and Webcast Details
The conference call will begin at 15:00 CET / 9:00 EDT on July 28, 2017. Interested parties may listen to the call by dialing: +1 760 294 1674 (U.S.), +44 203 059 5869 (UK), +49 69 566 037 000 (Germany)
The webcast will be accessible at www.qiagen.com/de/about-us/investors/corporate-calendar.
A conference call replay will be available through August 4, 2017, by dialing: +1 724 5589 653 (U.S.), +44 121 260 4861 (UK), +49 69 710 488 70 (Germany) (passcode: 345794#).
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2017, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
View original content:http://www.prnewswire.com/news-releases/qiagen-nv-to-report-second-quarter-and-first-half-of-2017-results-300487699.html
Subscribe to our Free Newsletters!
Malaria is a dangerous disease with lethal consequences that requires protective measures for ...
Merkel cell carcinoma is a rare and a highly aggressive primary skin cancer that grows rapidly and ...
Vitrectomy is a surgical procedure performed to remove a part or whole of the vitreous humor ...View All